Cibinqo Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Cibinqo Indications
Indications
In patients with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
Limitations of Use
Cibinqo Dosage and Administration
Adult
Children
<12yrs: not established.
Cibinqo Contraindications
Contraindications
Cibinqo Boxed Warnings
Boxed Warning
Cibinqo Warnings/Precautions
Warnings/Precautions
Cibinqo Pharmacokinetics
Absorption
Abrocitinib is absorbed with over 91% extent of oral absorption and absolute oral bioavailability of ~60%. The peak plasma concentrations of abrocitinib are reached within 1 hour.
Distribution
After intravenous administration, the volume of distribution of abrocitinib is ~100 L. Approximately 64%, 37% and 29% of circulating abrocitinib and its active metabolites M1 and M2, respectively, are bound to plasma proteins. Abrocitinib and its active metabolites M1 and M2 bind predominantly to albumin and distribute equally between red blood cells and plasma.
Elimination
Primarily eliminated by metabolic clearance mechanisms. The mean elimination half-lives of abrocitinib and its two active metabolites, M1 and M2, range 3–5 hours. The metabolites of abrocitinib, M1 and M2 are excreted predominantly in urine, and are substrates of OAT3 transporter.
Cibinqo Interactions
Interactions
Cibinqo Adverse Reactions
Adverse Reactions
Cibinqo Clinical Trials
See Literature
Cibinqo Note
Not Applicable
Cibinqo Patient Counseling
See Literature